Kura Oncology Q2 net loss widens to $66.1M; FDA sets Nov 30 PDUFA for ziftomenib NDA

Kura Oncology, Inc.

2025-Q2 EPS reported -$1.41 vs consensus -$0.47 ▼ miss (-201.2%)

Net loss $66.1M in Q2 2025 vs $50.8M in Q2 2024; collaboration revenue $15.3M from Kyowa Kirin.
FDA Priority Review for ziftomenib NDA; PDUFA target action date Nov 30, 2025.
Cash, equivalents and investments $630.7M as of June 30; expected to fund operations into 2027, plus Kyowa Kirin funding.
Phase 3 KOMET-017 trials and first KO-2806/FTI data expected in 2H 2025 at ESMO.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.